| pubmed-article:15510836 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:15510836 | lifeskim:mentions | umls-concept:C0087111 | lld:lifeskim |
| pubmed-article:15510836 | lifeskim:mentions | umls-concept:C0023473 | lld:lifeskim |
| pubmed-article:15510836 | lifeskim:mentions | umls-concept:C1522642 | lld:lifeskim |
| pubmed-article:15510836 | lifeskim:mentions | umls-concept:C0432412 | lld:lifeskim |
| pubmed-article:15510836 | lifeskim:mentions | umls-concept:C0935989 | lld:lifeskim |
| pubmed-article:15510836 | lifeskim:mentions | umls-concept:C1552913 | lld:lifeskim |
| pubmed-article:15510836 | pubmed:issue | 9 | lld:pubmed |
| pubmed-article:15510836 | pubmed:dateCreated | 2004-10-29 | lld:pubmed |
| pubmed-article:15510836 | pubmed:abstractText | An increase in the presence of the Ph-negative, trisomy 8 clone has been reported in chronic myelogenous leukemia (CML) under imatinib therapy, but any impact of the clone on patient prognosis remains uncertain. We report here on a 42-year-old male with CML who received imatinib after failure of interferon-alpha therapy. A chromosomal analysis revealed 18/20 trisomy 8 in bone marrow at 10 months of imatinib administration. Continuing imatinib at 300 mg daily resulted in a decrease in the number of trisomy 8 clones as well as the disappearance of Ph clone. Furthermore, the patient's pancytopenia was gradually improved. Imatinib therapy could be continued even with the emergence of trisomy 8. | lld:pubmed |
| pubmed-article:15510836 | pubmed:language | jpn | lld:pubmed |
| pubmed-article:15510836 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:15510836 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:15510836 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:15510836 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:15510836 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:15510836 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:15510836 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:15510836 | pubmed:month | Sep | lld:pubmed |
| pubmed-article:15510836 | pubmed:issn | 0485-1439 | lld:pubmed |
| pubmed-article:15510836 | pubmed:author | pubmed-author:NöllG NGN | lld:pubmed |
| pubmed-article:15510836 | pubmed:author | pubmed-author:KimuraFumihik... | lld:pubmed |
| pubmed-article:15510836 | pubmed:author | pubmed-author:MotoyoshiKazu... | lld:pubmed |
| pubmed-article:15510836 | pubmed:author | pubmed-author:KobayashiShin... | lld:pubmed |
| pubmed-article:15510836 | pubmed:author | pubmed-author:KobayashiAyak... | lld:pubmed |
| pubmed-article:15510836 | pubmed:author | pubmed-author:IkedaTakashiT | lld:pubmed |
| pubmed-article:15510836 | pubmed:author | pubmed-author:OguraKazutoK | lld:pubmed |
| pubmed-article:15510836 | pubmed:author | pubmed-author:TorikaiHiroki... | lld:pubmed |
| pubmed-article:15510836 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:15510836 | pubmed:volume | 45 | lld:pubmed |
| pubmed-article:15510836 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:15510836 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:15510836 | pubmed:pagination | 1058-60 | lld:pubmed |
| pubmed-article:15510836 | pubmed:dateRevised | 2007-11-15 | lld:pubmed |
| pubmed-article:15510836 | pubmed:meshHeading | pubmed-meshheading:15510836... | lld:pubmed |
| pubmed-article:15510836 | pubmed:meshHeading | pubmed-meshheading:15510836... | lld:pubmed |
| pubmed-article:15510836 | pubmed:meshHeading | pubmed-meshheading:15510836... | lld:pubmed |
| pubmed-article:15510836 | pubmed:meshHeading | pubmed-meshheading:15510836... | lld:pubmed |
| pubmed-article:15510836 | pubmed:meshHeading | pubmed-meshheading:15510836... | lld:pubmed |
| pubmed-article:15510836 | pubmed:meshHeading | pubmed-meshheading:15510836... | lld:pubmed |
| pubmed-article:15510836 | pubmed:meshHeading | pubmed-meshheading:15510836... | lld:pubmed |
| pubmed-article:15510836 | pubmed:meshHeading | pubmed-meshheading:15510836... | lld:pubmed |
| pubmed-article:15510836 | pubmed:meshHeading | pubmed-meshheading:15510836... | lld:pubmed |
| pubmed-article:15510836 | pubmed:meshHeading | pubmed-meshheading:15510836... | lld:pubmed |
| pubmed-article:15510836 | pubmed:year | 2004 | lld:pubmed |
| pubmed-article:15510836 | pubmed:articleTitle | [Emergence and decrement of Ph-negative clone with trisomy 8 in CML during imatinib therapy]. | lld:pubmed |
| pubmed-article:15510836 | pubmed:affiliation | Third Department of Internal Medicine, National Defense Medical College. | lld:pubmed |
| pubmed-article:15510836 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:15510836 | pubmed:publicationType | English Abstract | lld:pubmed |
| pubmed-article:15510836 | pubmed:publicationType | Case Reports | lld:pubmed |
